Clinical trial
A Phase I/Ib Study Evaluating the Efficacy and Safety of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Combination With TGR-1202, a Novel PI3k Delta Inhibitor; and Ibrutinib or Bendamustine, in Patients With B-cell Malignancies.
NCT02006485 is registered in ClinicalTrials.gov with TG Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/Ib Study Evaluating the Efficacy and Safety of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Combination With TGR-1202, a Novel PI3k Delta Inhibitor; and Ibrutinib or Bendamustine, in Patients With B-cell Malignancies.
- Lead sponsor
- TG Therapeutics, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 13, 2013
- Completion date
- October 31, 2019
- Enrollment
- 160 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
chronic lymphocytic leukemia, non-hodgkin's lymphoma